Adalimumab (Humira) Receives FDA Approval

The U.S. Food and Drug Administration (FDA) approved Humira (adalimumab, previously D2E7) for the reduction in signs and symptoms and the inhibition of structural damage in adults with moderately to severely active rheumatoid arthritis who have failed one or more DMARDs. Humira is a human monoclonal antibody that specifically blocks tumor necrosis factor alpha (TNF-a). (read more about TNF inhibitors)

Approval of Humira from the European Agency for the Evaluation of Medicinal Products (EAEM) is currently under review.

All information contained within the Johns Hopkins Arthritis Center website is intended for educational purposes only. Physicians and other health care professionals are encouraged to consult other sources and confirm the information contained within this site. Consumers should never disregard medical advice or delay in seeking it because of something they may have read on this website.